Good MorningEquities hovered near break even on Thursday following another decline in the Index of Leading Indicators. The index fell-0.4% in the Month of July making it the 4th straight month of decline but there is some good news. The -0.4% is a better read than the -0.5% indicated by the consensus estimate and an improvement from the prior months -0.7%. If this turns into a trend economic expansion could be back on the table by the end of the quarter but it is too soon to tell.
Next week could be a tough one for the market. There are very few earnings reports on the schedule but at least one major economic report that could move the market. The PCE price index is due out on Friday and will give the latest read on consumer inflation. A better-than-expected report will send the market higher. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Healthcare | | Pharmaceutical stocks are frequently subject to whiplash trade, and that’s evident now with sharp moves lower in names such as Sanofi (NASDAQ: SNY), GSK (NYSE: GSK), and Teva Pharmaceuticals (NYSE: TEVA).
Price swings in that industry are often determined by the results of clinical trials or... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Industrials | | If you’ve ever gotten a speed, red light, or school bus camera ticket in the mail, then you know how miserable they can be. At some point, you think to yourself that there’s got to be someone on the other side making a ton of money off these tickets. Well, there is a company making a ton... Read the Full Story |
|
Consumer Discretionary | |
The institutional support for TJX Companies (NYSE: TJX) remains high at 91.5% but their activity may cap gains in the near term. The institutions have been net-sellers for the last two consecutive quarters and that trend may not end with the Q2 earnings report. While the selling is light at only $... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Consumer Discretionary | |
I have a background in marketing. So it’s impossible for me to ignore the loyalty that Starbucks (NASDAQ:SBUX) receives from its customers. It shows up in my social media feed for sure. But I also notice that, even in the small-ish area I live in, Starbucks continues to expand, or at least r... Read the Full Story |
|
Consumer Staples | |
BJ’s (NYSE: BJ) Wholesale Club Q2 results echo the strength seen in Sam’s Club segment at Walmart (NYSE: WMT). The two membership clubs posted record results driven by rising member counts that are underpinning a robust outlook for the year. Assuming these trends are true across the di... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Technology | |
When it comes to the tech world there’s established, blue-chip tech and then there’s experimental tech and Cisco Systems (NASDAQ: CSCO) is as established as a company can be. The company manufactures, markets, and services IP-based networking, routing, and infrastructure components use... Read the Full Story |
|
Technology | | It’s been a rollercoaster of a summer for Micron (NASDAQ: MU) investors, who’ve had to watch their shares fall 30% and then rally 30% in the past two months alone. But there are signs that the worst of the volatility might now be behind them. This will be a welcome turn of events for all... Read the Full Story |
|
Technology | | ON Semiconductor (NASDAQ: ON) has taken a leadership role within its industry lately, as the stock notched gains of 26.11% in the past month and 28.21% in the past three months.
Other large-cap chip companies, such as Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD) have shown fundam... Read the Full Story |
|
Materials | | Metal miner Rio Tinto (NYSE: RIO) is up 7.8% since reporting first-half earnings in late July. Earnings declined 29%, to $2.73 per share, while revenue dropped 10% to $14.9 billion.
Although that was actually an earnings beat, the company also slashed its dividend in response to lower iron ore pri... Read the Full Story |
|
Industrials | |
If you've ever had an interest in business aviation, combat vehicles, weapons systems and munitions or shipbuilding and ship repair, General Dynamics Corporation (NYSE: GD) might be right up your alley.
General Dynamics pays an annual dividend of $5.04 per share and has a dividend yield of 2.1%.... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. | | View Today's Stock Pick |
|
